Tibor Keler, Ph.D., is a distinguished immunologist and biopharmaceutical executive who currently holds the position of Executive Vice President and Chief Scientific Officer at Celldex Therapeutics Inc. With a robust academic background, Dr. Keler earned his Ph.D. in Immunology from the University of Pennsylvania, where he honed his expertise in the intricate mechanisms of the immune system. His career trajectory has been marked by significant contributions to the field of oncology and immunotherapy, reflecting his deep commitment to advancing cancer treatment through innovative research and development. Before joining Celldex, Dr. Keler held pivotal roles at several leading biotech firms, where he spearheaded the development of novel therapeutic agents. His work has been instrumental in the progression of multiple clinical-stage programs targeting various cancers, including those focused on antibody-drug conjugates and bispecific antibodies. At Celldex, Dr. Keler oversees the company's scientific strategy and leads a team of researchers dedicated to developing targeted immunotherapies. His leadership has been crucial in advancing Celldex's pipeline, notably with the development of their lead candidate, which has shown promising results in clinical trials for the treatment of glioblastoma and other solid tumors. Dr. Keler's achievements extend beyond his corporate roles, as he is an active contributor to the scientific community through his numerous publications and presentations at international conferences. His work has been recognized for its impact on the understanding and treatment of cancer, earning him respect and admiration among his peers. As the Chief Scientific Officer at Celldex, Dr. Keler continues to drive the company's mission to bring transformative therapies to patients, leveraging his extensive experience and visionary approach to scientific innovation.